by Truveta Research | Aug 23, 2024 | Research, Research Insights
Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
by Truveta staff | Feb 22, 2024 | Data, Technology
The National Academy of Medicine has estimated that less than half of all medical care in the US is supported by adequate evidence of effectiveness. The proliferation of treatment options in some disease states and the rising costs of many of those treatments have...
by Truveta staff | Nov 21, 2023 | Data
ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta Research | Nov 2, 2023 | Research, Research Insights
Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
